MARK4 Antibody (YA7937)(PBS only)

Microtubule affinity-regulating kinase 4 (MARK4) is a Ser/Thr protein kinase that phosphorylates microtubule-associated proteins, thereby modulating microtubule stability and cytoskeletal dynamics^[1][2]. Mechanistically, MARK4 influences multiple signaling pathways, including Hippo, mammalian target of rapamycin (mTOR), and nuclear factor-κB (NF-κB), which coordinate cell proliferation, survival, and migration^[1]. In disease models, MARK4 contributes to tumorigenesis by acting as a negative regulator of the Hippo-kinase cassette, promoting YAP/TAZ nuclear activity and cancer cell growth^[1]. MARK4 also mediates tau hyperphosphorylation at Ser262/356, a process implicated in neurodegenerative disorders such as Alzheimer's disease^[2]. Compared with related isoforms MARK1-3, MARK4 exhibits unique substrate specificity and tissue distribution, highlighting its distinct biological functions and therapeutic relevance^[1][2]. Selective inhibition of MARK4 has demonstrated efficacy in experimental models of cancer and neurodegeneration, with small-molecule inhibitors attenuating pathological signaling without broadly affecting other MARK isoforms^[1]. For experimental applications, MARK4 activity can be monitored via tau phosphorylation assays, microtubule-binding assessments, and pathway-specific readouts to evaluate pharmacological modulation^[2]. Collectively, MARK4 serves as a pivotal kinase integrating cytoskeletal regulation with disease-relevant signaling networks, offering a specific target for mechanistic studies and drug development^[1][2].